3D Signatures Announces Appointment of Dr. Kevin Little as Chief Scientific Officer
April 11 2017 - 8:15AM
3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the
"Company" or "3DS"), is pleased to announce the appointment of Dr.
Kevin Little, subject to approval of the TSX Venture Exchange, a
leading biomedical scientist and corporate executive, as its new
Chief Scientific Officer (“CSO”), effective immediately. In
this role, Dr. Little will oversee the design, development and
implementation of the Company’s clinical programs.
Dr. Little is an accomplished industry executive
with a strong history of success in leading life sciences ventures
through the creation of collaborative business ecosystems. Prior to
his position at 3DS, Dr. Little worked as an independent
consultant, offering strategic advisory services to help facilitate
new life sciences collaborations and research-related ecosystems
for public and private sector clients, including Thomson Reuters,
Illumina, Janssen, McGill University and the Global Alliance for
Genomics and Health. Dr. Little previously led strategic planning
for the PERFORM Centre, a $36 Million health research and community
services complex, as the Founding Chief Administrative Officer.
There, he established and oversaw all operations across nine
business units. Before returning to Canada to lead the
start-up of the PERFORM Centre, Dr. Little spent several years
leading the New Zealand government’s economic development efforts
to build strategic investment relationships across the
biotechnology industry sector.
Dr. Little holds a Bachelor of Science degree in
Biology from the University of Victoria, and earned his Ph.D. in
Experimental Medicine from McGill University, specializing in DNA
repair and functional human genomics. During his Ph.D.
studies, he was part of a biotech start-up developing clinical
assays to map the functional organization of the human genome. Dr.
Little went on to complete a postdoctoral fellowship in
translational neuroscience and clinical gene therapy at the
University of Auckland in New Zealand, and is a Certified Strategic
Alliance Professional.
“With his unique combination of clinical and
executive expertise, Kevin is exceptionally well-qualified to lead
our clinical development programs as Chief Scientific Officer, and
we are thrilled that we attracted a candidate of his caliber to
this key position,” said Jason Flowerday, CEO of 3D Signatures.
“Kevin has an outstanding track record in helping life sciences
companies grow, and we look forward to working with him to bring
3DS’ transformational technology to market.”
“I’m thrilled to join 3DS, an innovative
personalized medicine company with a potentially game-changing
technology, at such an exciting stage,” commented Dr. Little. “3DS’
platform is fundamentally different from conventional diagnostic
methods, and represents an entirely new diagnostic paradigm. This
disruptive technology has the potential to dramatically improve
patient outcomes, something I’m very passionate about, while, at
the same time, reducing costs and improving resource use across the
healthcare system. I look forward to working with everyone at 3DS
to maximize the clinical and commercial potential of this exciting
new technology.”
In connection with Dr. Little’s appointment as
CSO, and pursuant to 3DS’ stock option plan, the Board of Directors
of the Company granted Dr. Little 25,000 stock options (the
“Options”), exercisable at $0.74, the closing price of the
Company’s shares on the TSX Venture Exchange on April 7, 2017.
The Options will vest in two tranches, 10,000 on April 10,
2018 and 15,000 on April 10, 2019. Once vested, the Options are
exercisable for ten years from the date of grant.
3DS also announced that it has granted 23,000
incentive stock options (the “Incentive Options”) to recently hired
employees of its subsidiary, 3D Signatures Holdings Inc., at an
exercise price of $0.74. The Incentive Options are exercisable for
a ten-year period from the date of the grant and will vest 50% in
April 2018 and 50% in April 2019, respectively.
About 3DS
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a
personalized medicine company with a proprietary software platform
based on the three-dimensional analysis of chromosomal signatures.
The technology is well developed and supported by 22 clinical
studies on over 2,000 patients on 13 different cancers and
Alzheimer’s disease. Depending on the desired application, this
platform technology can measure the stage of disease, rate of
progression of disease, drug efficacy, and drug toxicity. The
technology is designed to predict the course of disease and to
personalize treatment for the individual patient. For more
information, visit the Company’s new website at
http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking
statements that are subject to risks and uncertainties.
Forward-looking statements involve known and unknown risks,
uncertainties, and other factors that could cause the actual
results of the Company to be materially different from the
historical results or from any future results expressed or implied
by such forward-looking statements. All statements within, other
than statements of historical fact, are to be considered forward
looking. Although 3DS believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results or developments may differ materially from those in
forward-looking statements. Risk factors that could cause
actual results or outcomes to differ materially from the results
expressed or implied by forward-looking information include, among
other things: market demand; technological changes that could
impact the Company’s existing products or the Company’s ability to
develop and commercialize future products; competition; existing
governmental legislation and regulations and changes in, or the
failure to comply with, governmental legislation and
regulations; the ability to manage operating expenses, which
may adversely affect the Company’s financial condition; the
Company’s ability to successfully maintain and enforce its
intellectual property rights and defend third-party claims of
infringement of their intellectual property rights; adverse
results or unexpected delays in clinical trials; changes in
laws, general economic and business conditions; and changes in the
regulatory regime. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised
to rely on their own evaluation of such uncertainties. We do not
assume any obligation to update any forward-looking
statements.
Neither the TSX Venture Exchange nor its
Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Hugh Rogers
VP Corporate Finance
604-428-8842
investors@3dsignatures.com
OR
Stephen Kilmer
Investor Relations
647-872-4849
stephen.kilmer@3dsignatures.com
3D Signatures (TSXV:DXD)
Historical Stock Chart
From May 2024 to May 2024
3D Signatures (TSXV:DXD)
Historical Stock Chart
From May 2023 to May 2024